GARDNER JASON 4
4 · Magenta Therapeutics, Inc. · Filed Jun 27, 2018
Insider Transaction Report
Form 4
GARDNER JASON
DirectorSee Remarks
Transactions
- Conversion
Series B Preferred Stock
2018-06-25−15,000→ 0 total(indirect: By Trust)→ Common Stock (5,804 underlying) - Conversion
Series C Preferred Stock
2018-06-25−21,459→ 0 total(indirect: By Trust)→ Common Stock (8,304 underlying) - Conversion
Common Stock
2018-06-25+25,719→ 292,990 total(indirect: By Trust) - Purchase
Common Stock
2018-06-25$15.00/sh+400$6,000→ 363,212 total - Conversion
Series A Preferred Stock
2018-06-25−30,000→ 0 total(indirect: By Trust)→ Common Stock (11,611 underlying) - Conversion
Common Stock
2018-06-25+21,677→ 359,092 total(indirect: By Trust) - Conversion
Series A Preferred Stock
2018-06-25−36,700→ 0 total(indirect: By Trust)→ Common Stock (14,203 underlying) - Conversion
Series B Preferred Stock
2018-06-25−19,314→ 0 total(indirect: By Trust)→ Common Stock (7,474 underlying)
Footnotes (2)
- [F1]The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date.
- [F2]Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering.